Daiichi Sankyo Company (4568) Stock Overview
Manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,602.50 |
| 52 Week High | JP¥4,178.00 |
| 52 Week Low | JP¥2,443.00 |
| Beta | -0.18 |
| 1 Month Change | -13.25% |
| 3 Month Change | -11.51% |
| 1 Year Change | -30.27% |
| 3 Year Change | -45.68% |
| 5 Year Change | 1.60% |
| Change since IPO | 237.26% |
Recent News & Updates
Analysis Article • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...
Narrative Update • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.Recent updates
Analysis Article • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...Narrative Update • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.
Narrative Update • Apr 23
4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating
Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).Narrative Update • Apr 08
4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential
Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).
Narrative Update • Mar 25
4568: Oncology Pipeline Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).Narrative Update • Mar 11
4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).Narrative Update • Feb 25
4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).Narrative Update • Feb 10
4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating
Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).Analysis Article • Feb 08
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...Analysis Article • Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...Analysis Article • Feb 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...Narrative Update • Jan 26
4568: Oncology Approvals And Trials Will Drive Future Upside Potential
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.Analysis Article • Jan 23
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Narrative Update • Jan 12
4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).Analysis Article • Jan 09
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...Narrative Update • Dec 27
4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside
Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).Analysis Article • Dec 25
Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Narrative Update • Dec 13
4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside
Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.Analysis Article • Dec 11
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...Narrative Update • Nov 25
4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares
Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.Analysis Article • Nov 04
Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...Narrative Update • Oct 22
Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks
Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.Narrative Update • Oct 08
Global Aging And ADC Pipelines Will Expand Oncology Markets
Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.Analysis Article • Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...Analysis Article • Sep 05
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Narrative Update • Sep 04
Global Aging And ADC Pipelines Will Expand Oncology Markets
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.Analysis Article • Aug 22
Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Analysis Article • Aug 07
Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) will increase its dividend from last year's comparable payment on the 10th...Analysis Article • Aug 03
Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Daiichi Sankyo Company, Limited ( TSE:4568 ) investors will be delighted, with the company turning in some strong...Analysis Article • Jul 24
Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) dividend will be increasing from last year's payment of the same period...Analysis Article • Jul 09
Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) dividend will be increasing from last year's payment of the same period...Analysis Article • Jun 27
We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings
Despite posting some strong earnings, the market for Daiichi Sankyo Company, Limited's ( TSE:4568 ) stock hasn't moved...Analysis Article • Jun 18
Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 21.8x Daiichi Sankyo Company, Limited ( TSE:4568 ) may be sending very...Shareholder Returns
| 4568 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -4.5% | 0.3% | -0.5% |
| 1Y | -30.3% | 17.2% | 39.8% |
Return vs Industry: 4568 underperformed the JP Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: 4568 underperformed the JP Market which returned 39.8% over the past year.
Price Volatility
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in JP Market | 9.6% |
| 10% least volatile stocks in JP Market | 2.5% |
Stable Share Price: 4568 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4568's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 19,765 | Hiroyuki Okuzawa | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| 4568 fundamental statistics | |
|---|---|
| Market cap | JP¥4.80t |
| Earnings (TTM) | JP¥259.87b |
| Revenue (TTM) | JP¥2.12t |
18.2x
P/E Ratio2.2x
P/S RatioIs 4568 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4568 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.12t |
| Cost of Revenue | JP¥669.05b |
| Gross Profit | JP¥1.45t |
| Other Expenses | JP¥1.19t |
| Earnings | JP¥259.87b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 142.82 |
| Gross Margin | 68.49% |
| Net Profit Margin | 12.24% |
| Debt/Equity Ratio | 18.1% |
How did 4568 perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield56%
Payout RatioDoes 4568 pay a reliable dividends?
See 4568 dividend history and benchmarks| Daiichi Sankyo Company dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 23 2026 |
| Days until Ex dividend | 52 days |
| Days until Dividend pay date | 33 days |
Does 4568 pay a reliable dividends?
See 4568 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 14:08 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daiichi Sankyo Company, Limited is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |